{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T02:12:13Z","timestamp":1783649533874,"version":"3.55.0"},"reference-count":80,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T00:00:00Z","timestamp":1688515200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000057","name":"the National Institute of General Medical Sciences (NIGMS) of the National Institutes of Health (NIH)","doi-asserted-by":"publisher","award":["P20GM103434"],"award-info":[{"award-number":["P20GM103434"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Epigenomes"],"abstract":"<jats:p>Azanucleosides, such as 5-azacytidine and decitabine, are DNA demethylating agents used in the treatment of acute myeloid leukemia and myelodysplastic syndromes. Researchers continue to explore their utility in the treatment of other hematologic and solid tumors. Based on the capacity of the compounds to inhibit DNA methyltransferase enzymes and the important role of DNA methylation in health and disease, it is essential to understand the molecular changes that azanucleosides induce and how these changes may improve treatment outcomes in subsets of patients. This review summarizes the molecular and therapeutic actions of azanucleosides and discusses recent clinical trials of these compounds as single agents or in combination therapy for the treatment of cancer and related conditions.<\/jats:p>","DOI":"10.3390\/epigenomes7030012","type":"journal-article","created":{"date-parts":[[2023,7,6]],"date-time":"2023-07-06T00:34:30Z","timestamp":1688603670000},"page":"12","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Therapeutic Applications of Azanucleoside Analogs as DNA Demethylating Agents"],"prefix":"10.3390","volume":"7","author":[{"given":"Fallon","family":"Gallimore","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical & Administrative Sciences, School of Pharmacy, University of Charleston, Charleston, WV 25304, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamer E.","family":"Fandy","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical & Administrative Sciences, School of Pharmacy, University of Charleston, Charleston, WV 25304, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,7,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"657","DOI":"10.2217\/epi.10.44","article-title":"Molecular coupling of DNA methylation and histone methylation","volume":"2","author":"Hashimoto","year":"2010","journal-title":"Epigenomics"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13148-016-0237-y","article-title":"A clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancers","volume":"8","author":"Diesch","year":"2016","journal-title":"Clin. Epigenetics"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1248\/cpb.c22-00088","article-title":"An Update Mini-Review on the Progress of Azanucleoside Analogues","volume":"70","author":"Zhang","year":"2022","journal-title":"Chem. Pharm. Bull."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Stein, A., Platzbecker, U., and Cross, M. (2022). How Azanucleosides Affect Myeloid Cell Fate. Cells, 11.","DOI":"10.3390\/cells11162589"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Jung, M., and Pfeifer, G.P. (2015). Aging and DNA methylation. BMC Biol., 13.","DOI":"10.1186\/s12915-015-0118-4"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"6796","DOI":"10.1073\/pnas.1415301111","article-title":"Notes on the role of dynamic DNA methylation in mammalian development","volume":"112","author":"Bestor","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/mrd.21118","article-title":"DNA methylation in early development","volume":"77","author":"Geiman","year":"2010","journal-title":"Mol. Reprod. Dev."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2217\/epi.09.5","article-title":"Dynamic regulation of DNA methylation during mammalian development","volume":"1","author":"Guibert","year":"2009","journal-title":"Epigenomics"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1126\/science.1063443","article-title":"Epigenetic reprogramming in mammalian development","volume":"293","author":"Reik","year":"2001","journal-title":"Science"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1042\/EBC20200009","article-title":"Making it or breaking it: DNA methylation and genome integrity","volume":"64","author":"Sriraman","year":"2020","journal-title":"Essays Biochem."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7150\/ijbs.11218","article-title":"DNA methylation, its mediators and genome integrity","volume":"11","author":"Meng","year":"2015","journal-title":"Int. J. Biol. Sci."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/npp.2012.112","article-title":"DNA methylation and its basic function","volume":"38","author":"Moore","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Edwards, J.R., Yarychkivska, O., Boulard, M., and Bestor, T.H. (2017). DNA methylation and DNA methyltransferases. Epigenetics Chromatin, 10.","DOI":"10.1186\/s13072-017-0130-8"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1080\/15592294.2019.1638701","article-title":"DNA hypermethylation in disease: Mechanisms and clinical relevance","volume":"14","author":"Ehrlich","year":"2019","journal-title":"Epigenetics"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Martisova, A., Holcakova, J., Izadi, N., Sebuyoya, R., Hrstka, R., and Bartosik, M. (2021). DNA Methylation in Solid Tumors: Functions and Methods of Detection. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22084247"},{"key":"ref_16","first-page":"138","article-title":"DNA hypomethylation and human diseases","volume":"1775","author":"Wilson","year":"2007","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"13922","DOI":"10.18632\/oncotarget.4215","article-title":"DNA methylation and cognitive aging","volume":"6","author":"Xu","year":"2015","journal-title":"Oncotarget"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.pharmthera.2018.02.006","article-title":"Nucleosidic DNA demethylating epigenetic drugs\u2014A comprehensive review from discovery to clinic","volume":"188","author":"Agrawal","year":"2018","journal-title":"Pharmacol. Ther."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Mehdipour, P., Murphy, T., and De Carvalho, D.D. (2020). The role of DNA-demethylating agents in cancer therapy. Pharmacol. Ther., 205.","DOI":"10.1016\/j.pharmthera.2019.107416"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/ijc.23607","article-title":"Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine","volume":"123","author":"Stresemann","year":"2008","journal-title":"Int. J. Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1182\/bloodadvances.2019001245","article-title":"Clinical developments in epigenetic-directed therapies in acute myeloid leukemia","volume":"4","author":"Pan","year":"2020","journal-title":"Blood Adv."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Palacios-Berraquero, M.L., and Alfonso-Pierola, A. (2021). Current Therapy of the Patients with MDS: Walking towards Personalized Therapy. J. Clin. Med., 10.","DOI":"10.3390\/jcm10102107"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1182\/blood-2018-10-844696","article-title":"Treatment of MDS","volume":"133","author":"Platzbecker","year":"2019","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.3390\/ph3072022","article-title":"Demethylating Agents in the Treatment of Cancer","volume":"3","author":"Howell","year":"2010","journal-title":"Pharmaceuticals"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Sato, T., Issa, J.J., and Kropf, P. (2017). DNA Hypomethylating Drugs in Cancer Therapy. Cold Spring Harb. Perspect. Med., 7.","DOI":"10.1101\/cshperspect.a026948"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1002\/ijc.25635","article-title":"Azacytidine impairs NK cell reactivity while decitabine augments NK cell responsiveness toward stimulation","volume":"128","author":"Schmiedel","year":"2011","journal-title":"Int. J. Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1159\/000489702","article-title":"Myelodysplastic Syndrome Updated","volume":"86","author":"Hasserjian","year":"2019","journal-title":"Pathobiology"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"De Kouchkovsky, I., and Abdul-Hay, M. (2016). \u2018Acute myeloid leukemia: A comprehensive review and 2016 update\u2019. Blood Cancer J., 6.","DOI":"10.1038\/bcj.2016.50"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1634\/theoncologist.2012-0465","article-title":"Concise drug review: Azacitidine and decitabine","volume":"18","author":"Derissen","year":"2013","journal-title":"Oncologist"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1586\/era.09.61","article-title":"Azacitidine for the treatment of myelodysplastic syndrome","volume":"9","author":"Cataldo","year":"2009","journal-title":"Expert. Rev. Anticancer. Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/ajh.2830430411","article-title":"Mitoxantrone and 5-azacytidine for refractory\/relapsed ANLL or CML in blast crisis: A leukemia intergroup study","volume":"43","author":"Goldberg","year":"1993","journal-title":"Am. J. Hematol."},{"key":"ref_32","first-page":"319","article-title":"Treatment of acute leukemia with 5-azacytidine (NSC-102816)","volume":"57","author":"McCredie","year":"1973","journal-title":"Cancer Chemother. Rep."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1002\/1097-0142(19810401)47:7<1739::AID-CNCR2820470702>3.0.CO;2-2","article-title":"Effect of schedule on activity and toxicity of 5-azacytidine in acute leukemia: A Southwest Oncology Group Study","volume":"47","author":"Saiki","year":"1981","journal-title":"Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1182\/blood.V48.3.331.331","article-title":"5-Azacytidine (NSC 102816): A new drug for the treatment of myeloblastic leukemia","volume":"48","author":"Vogler","year":"1976","journal-title":"Blood"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1200\/JCO.2002.04.117","article-title":"Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the cancer and leukemia group B","volume":"20","author":"Silverman","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"ref_36","unstructured":"Silverman, L.R., Holland, J.F., Demakos, E.P., and Al, E. (1994). Azacitidine (Aza C) in myelodysplastic syndromes (MDS), CALGB studies 8421 and 8921. Ann. Hematol., 68."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3895","DOI":"10.1200\/JCO.2005.05.4346","article-title":"Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: Studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B","volume":"24","author":"Silverman","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2147\/DDDT.S3143","article-title":"Safety and efficacy of azacitidine in myelodysplastic syndromes","volume":"4","author":"Vigil","year":"2010","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: A randomised, open-label, phase III study","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Fenaux, P., Mufti, G.J., Santini, V., Finelli, C., Giagounidis, A., Schoch, R., List, A.F., Gore, S.D., Seymour, J.F., and Hellstrom-Lindberg, E. (2007). Azacitidine treatments prolong overall survival in higher risk MDS patients compared with conventional care regimens: Results of the AZA-001 phase III study. Blood, 110.","DOI":"10.1182\/blood.V110.11.817.817"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"303","DOI":"10.3324\/haematol.2009.010611","article-title":"5-azacitidine prolongs overall survival in patients with myelodysplastic syndrome\u2014A systematic review and meta-analysis","volume":"95","author":"Gurion","year":"2010","journal-title":"Haematologica"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1200\/JCO.2000.18.5.956","article-title":"Low-dose 5-aza-2\u2032-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: A multicenter phase II study in elderly patients","volume":"18","author":"Wijermans","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"ref_43","first-page":"30","article-title":"5-Aza-2\u2032-deoxycytidine (Decitabine) induces trilineage response in unfavourable myelodysplastic syndromes","volume":"7","author":"Zagonel","year":"1993","journal-title":"Leukemia"},{"key":"ref_44","first-page":"1","article-title":"An update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromes","volume":"3","author":"Garcia","year":"2010","journal-title":"Onco Targets Ther."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/cncr.21792","article-title":"Decitabine improves patient outcomes in myelodysplastic syndromes: Results of a phase III randomized study","volume":"106","author":"Kantarjian","year":"2006","journal-title":"Cancer"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute Myeloid Leukemia","volume":"373","author":"Dohner","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1002\/cncr.21723","article-title":"Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: Predictive prognostic models for outcome","volume":"106","author":"Kantarjian","year":"2006","journal-title":"Cancer"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1200\/JCO.2014.55.1564","article-title":"Acute myeloid leukemia and myelodysplastic syndromes in older adults","volume":"32","author":"Klepin","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.leukres.2014.11.027","article-title":"Finding the optimal combination therapy for the treatment of newly diagnosed AML in older patients unfit for intensive therapy","volume":"39","author":"Erba","year":"2015","journal-title":"Leuk. Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1002\/cncr.29367","article-title":"Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia","volume":"121","author":"Kadia","year":"2015","journal-title":"Cancer"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1182\/asheducation-2014.1.14","article-title":"Treating acute myeloid leukemia in older adults","volume":"2014","author":"Wang","year":"2014","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"41498","DOI":"10.18632\/oncotarget.17241","article-title":"Efficacy and safety of decitabine in treatment of elderly patients with acute myeloid leukemia: A systematic review and meta-analysis","volume":"8","author":"He","year":"2017","journal-title":"Oncotarget"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1158\/1535-7163.MCT-09-1048","article-title":"S110, a 5-Aza-2\u2032-deoxycytidine-containing dinucleotide, is an effective DNA methylation inhibitor in vivo and can reduce tumor growth","volume":"9","author":"Chuang","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1358\/dof.2013.38.8.1980499","article-title":"SGI-110: DNA Methyltransferase Inhibitor Oncolytic","volume":"38","author":"Griffiths","year":"2013","journal-title":"Drugs Future"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.2217\/epi.15.66","article-title":"Will next-generation agents deliver on the promise of epigenetic hypomethylation therapy?","volume":"7","author":"Lowder","year":"2015","journal-title":"Epigenomics"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"7473","DOI":"10.1073\/pnas.1002650107","article-title":"Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine","volume":"107","author":"Blum","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/S1470-2045(15)00038-8","article-title":"Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: A multicentre, randomised, dose-escalation phase 1 study","volume":"16","author":"Issa","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/cncr.31138","article-title":"Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia","volume":"124","author":"Roboz","year":"2018","journal-title":"Cancer"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/S1470-2045(17)30576-4","article-title":"Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: Phase 2 results from a multicentre, randomised, phase 1\/2 trial","volume":"18","author":"Kantarjian","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.3324\/haematol.2018.207118","article-title":"A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure","volume":"104","author":"Sebert","year":"2019","journal-title":"Haematologica"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Hu, C., Liu, X., Zeng, Y., Liu, J., and Wu, F. (2021). DNA methyltransferase inhibitors combination therapy for the treatment of solid tumor: Mechanism and clinical application. Clin. Epigenetics, 13.","DOI":"10.1186\/s13148-021-01154-x"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.stem.2012.12.013","article-title":"BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells","volume":"12","author":"Lagadinou","year":"2013","journal-title":"Cell Stem Cell"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1038\/leu.2014.44","article-title":"BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies","volume":"28","author":"Bogenberger","year":"2014","journal-title":"Leukemia"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.ccell.2018.10.005","article-title":"Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells","volume":"34","author":"Jones","year":"2018","journal-title":"Cancer Cell"},{"key":"ref_65","first-page":"166","article-title":"Histone deacetylase inhibitors: Molecular mechanisms of action and clinical trials as anti-cancer drugs","volume":"3","author":"Kim","year":"2011","journal-title":"Am. J. Transl. Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1158\/0008-5472.CAN-15-2249","article-title":"Combined Inhibition of DNMT and HDAC Blocks the Tumorigenicity of Cancer Stem-like Cells and Attenuates Mammary Tumor Growth","volume":"76","author":"Pathania","year":"2016","journal-title":"Cancer Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/nrm1963","article-title":"Poly(ADP-ribose): Novel functions for an old molecule","volume":"7","author":"Schreiber","year":"2006","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1158\/1078-0432.CCR-18-0204","article-title":"An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations","volume":"24","author":"Pulliam","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Dhillon, S. (2021). Correction to: Decitabine\/Cedazuridine: First Approval. Drugs, 81.","DOI":"10.1007\/s40265-020-01453-2"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1182\/bloodadvances.2020002929","article-title":"Cedazuridine\/decitabine: From preclinical to clinical development in myeloid malignancies","volume":"5","author":"Patel","year":"2021","journal-title":"Blood Adv."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.2217\/fon-2020-1210","article-title":"Role of cedazuridine\/decitabine in the management of myelodysplastic syndrome and chronic myelomonocytic leukemia","volume":"17","author":"Thota","year":"2021","journal-title":"Future Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Stahl, M., and Goldberg, A.D. (2019). Immune Checkpoint Inhibitors in Acute Myeloid Leukemia: Novel Combinations and Therapeutic Targets. Curr. Oncol. Rep., 21.","DOI":"10.1007\/s11912-019-0781-7"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.cell.2015.07.011","article-title":"Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses","volume":"162","author":"Chiappinelli","year":"2015","journal-title":"Cell"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1182\/blood-2017-06-788497","article-title":"Randomized phase 2 study of low-dose decitabine vs. low-dose azacitidine in lower-risk MDS and MDS\/MPN","volume":"130","author":"Jabbour","year":"2017","journal-title":"Blood"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1200\/JCO.20.02341","article-title":"Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes","volume":"39","author":"Sallman","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13148-021-01226-y","article-title":"Pembrolizumab plus azacitidine in patients with chemotherapy refractory metastatic colorectal cancer: A single-arm phase 2 trial and correlative biomarker analysis","volume":"14","author":"Kuang","year":"2022","journal-title":"Clin. Epigenetics"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1158\/1078-0432.CCR-19-1638","article-title":"A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer","volume":"26","author":"Oza","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1093\/annonc\/mds591","article-title":"Safety and efficacy of decitabine in combination with temozolomide in metastatic melanoma: A phase I\/II study and pharmacokinetic analysis","volume":"24","author":"Tawbi","year":"2013","journal-title":"Ann. Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1182\/blood-2011-03-341909","article-title":"A pilot study of subcutaneous decitabine in beta-thalassemia intermedia","volume":"118","author":"Olivieri","year":"2011","journal-title":"Blood"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1182\/bloodadvances.2020002790","article-title":"Low-dose decitabine for refractory prolonged isolated thrombocytopenia after HCT: A randomized multicenter trial","volume":"5","author":"Tang","year":"2021","journal-title":"Blood Adv."}],"container-title":["Epigenomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4655\/7\/3\/12\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:06:46Z","timestamp":1760126806000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4655\/7\/3\/12"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,5]]},"references-count":80,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,9]]}},"alternative-id":["epigenomes7030012"],"URL":"https:\/\/doi.org\/10.3390\/epigenomes7030012","relation":{},"ISSN":["2075-4655"],"issn-type":[{"value":"2075-4655","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,5]]}}}